株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

血液スクリーニングの世界市場予測 (〜2019年):NAT検査・ELISA・ラピッドテスト・化学発光免疫測定・次世代シーケンシング・ウェスタンブロッティング

Blood Screening Market by Technology (Nucleic Acid Amplification Test, ELISA, Rapid Test, Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting), Product (Instrument, Reagent) & End User (Blood Bank, Hospital) - Forecasts to 2019

発行 MarketsandMarkets 商品コード 326050
出版日 ページ情報 英文 206 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
血液スクリーニングの世界市場予測 (〜2019年):NAT検査・ELISA・ラピッドテスト・化学発光免疫測定・次世代シーケンシング・ウェスタンブロッティング Blood Screening Market by Technology (Nucleic Acid Amplification Test, ELISA, Rapid Test, Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting), Product (Instrument, Reagent) & End User (Blood Bank, Hospital) - Forecasts to 2019
出版日: 2015年03月11日 ページ情報: 英文 206 Pages
概要

2014年から2019年にかけて血液スクリーニングの市場は10.4%のCAGRで推移し、2014年の15億5000万ドルから2019年には25億4000万ドルの規模に成長すると予測されています。この大きな成長の要因には、献血の件数および献血者数の増加、献血血液の安全性に対する認識の向上、NAT検査済み血液への支払い許容度の改善、NAT検査の導入率の拡大、献血血液の需要の増加、感染症の発症率・罹患率の増加などがあります。

当レポートでは、血液スクリーニングの世界市場について調査し、血液スクリーニングの主な手法とその概要、技術・製品&サービス区分・エンドユーザー別の市場規模の推移と予測、地域および主要国の動向、市場成長への各種影響因子および市場機会の分析、競合環境と市場シェア、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

  • 魅力的な市場機会
  • 血液スクリーニング市場:技術別
  • 製品・サービス別市場
  • 血液スクリーニング試薬市場
  • ELISA法市場
  • 血液スクリーニング市場:エンドユーザー別
  • 地域概要

第5章 市場概要

  • イントロダクション
  • 市場区分
    • 技術別
    • 製品・サービス別
    • エンドユーザー別
    • 地域別
  • 市場力学
    • 成長推進因子
    • 成長阻害因子
    • 市場機会
    • 課題
    • 緊急課題

第6章 産業動向

  • サプライチェーン分析
  • PEST分析
  • ポーターのファイブフォース分析

第7章 血液スクリーニングの世界市場:技術別

  • イントロダクション
  • 血液スクリーニング市場:検査件数
    • 転写介在増幅法 (TMA:Transcription Mediated Amplification)
    • リアルタイムPCR (Real-Time Polymerase Chain Reaction)
  • 酵素結合免疫吸着法(ELISA:Enzyme-Linked Immunosorbent Assay)
    • ラピッドテスト (カード法)
    • 第1世代ELISA
    • 第2世代ELISA
    • 第3世代ELISA
    • 第4世代ELISA
  • 次世代シーケンシング (NGS)
  • ウェスタンブロットアッセイ

第8章 血液スクリーニングの世界市場:製品・サービス別

  • イントロダクション
  • 機器 (ハードウェア)
    • レンタル購入
    • 買い切り
  • 試薬
    • ELISA試薬
      • 免疫吸着剤
      • コントロール
      • 抱合体 (抗原・抗体抱合酵素)
      • 基質 (酵素基質)
      • サンプル希釈剤・洗浄液
    • NAT試薬
      • 酵素・ポリメラーゼ
      • スタンダード・コントロール
      • プローブ・プライマー
      • バッファ・ヌクレオチド・ソリューション
      • ラベリング&検出試薬
    • その他の試薬
  • ソフトウェア・サービス

第9章 血液スクリーニングの世界市場:エンドユーザー別

  • イントロダクション
  • 血液バンク
  • 病院

第10章 血液スクリーニングの世界市場:地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • その他
  • アジア
    • 日本
    • 中国
    • インド
    • その他
  • その他の地域

第11章 競合環境

  • 概要
  • 市場シェア分析
    • NAT
    • 血液スクリーニング
  • 競合状況・動向
    • 新製品の発売
    • 承認
    • 提携・合意

第12章 企業プロファイル

  • イントロダクション
  • Grifols
  • Roche Diagnostics (A Division of F. Hoffmann-La Roche Ltd)
  • Abbott Laboratories
  • Biomerieux
  • Bio-Rad Laboratories, Inc.
  • Siemens Healthcare (Subsidiary of Siemens AG)
  • Ortho-Clinical Diagnostics, Inc.
  • Thermo Fisher Scientific, Inc.
  • Beckman Coulter (Subsidiary of Danaher Corporation)
  • Becton, Dickinson and Company
    • 事業概要
    • 製品
    • 主要戦略
    • 近年の発展動向、など

第13章 付録

目次
Product Code: BT 3228

The blood screening market size is expected to reach $2.55 billion by 2019 from $1.5 billion in 2014, at a CAGR of 10.4%. This market is categorized on the basis of products and services, technologies, end users, and regions. On the basis of products and services, the blood screening market is categorized into instruments (hardware), reagents, and software and services. The reagents segment accounted for the largest share of the blood screening market and is expected to grow at the highest CAGR in the coming five years. The increasing adoption rate of NAT, rising number of blood donations, disposable nature of reagents, and growing demand of blood for transfusion are driving the growth of this segment.

The major factors contributing to the growth of the blood screening market include increasing number of blood donations and blood donors, increasing awareness regarding the safety of donated blood, increasing patient affordability, and increasing demand of donated blood. Furthermore, increasing adoption of NAT by governments of various countries is another major factor providing impetus for growth of this market. For instance, in 2014, the Japanese Red Cross entered into an agreement with Grifols (Spain) for nucleic acid testing (NAT) for the total blood donated in Japan. This agreement is expected to aid the growth of the blood screening market during the forecast period.

Apart from comprehensive regional and product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise basic views on the key players in the blood screening market and product portfolios, developments, and strategies adopted by market players to maintain and increase their market shares in the near future. The above-mentioned market research data, current market size, and forecast of future trends will help key players and new entrants to make the necessary decisions regarding product offerings, regional focus, change in strategic approach, R&D investments for innovations in products and technologies, and levels of output in order to remain successful.

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help the firms, garner a greater market share. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on product portfolios of the top players in the blood screening market. The report analyzes the blood screening market by products and services, technology, end user, and region
  • Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and new product launches in the blood screening market
  • Competitive Assessment: In-depth assessment of the market strategies, regional and business segments, and product portfolios of the leading players in the blood screening market
  • Market Development: Comprehensive information about the lucrative emerging markets. The report analyzes the market for various blood screening products across regions
  • Market Diversification: Exhaustive information about new products and services, untapped regions, recent developments, and investments in the blood screening market

Table of Contents

1. Introduction

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Scope
    • 1.3.1. Markets Covered
    • 1.3.2. Years Considered for the Study
  • 1.4. Currency
  • 1.5. Stakeholders

2. Research Methodology

  • 2.1. Market Size Estimation
  • 2.2. Market Breakdown and Data Triangulation
  • 2.3. Market Share Estimation
  • 2.4. Key Data From Secondary Sources
  • 2.5. Key Data From Primary Sources
  • 2.6. Key Industry Insights
  • 2.7. Assumptions for the Study

3. Executive Summary

4. Premium Insights

  • 4.1. Blood Screening Market, By Technology
  • 4.2. By Products and Services
  • 4.3. Blood Screening Reagents Market
  • 4.4. Blood Screening ELISA Market
  • 4.5. Blood Screening Market, By End User
  • 4.6. Geographic Snapshot

5. Market Overview

  • 5.1. Introduction
  • 5.2. Market Segmentation
    • 5.2.1. Blood Screening Market Segmentation, By Technology
    • 5.2.2. Market Segmentation, By Products and Services
    • 5.2.3. Market Segmentation, By End User
    • 5.2.4. Market Segmentation, By Region
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
      • 5.3.1.1. Increasing Number of Blood Donations and Blood Donors
      • 5.3.1.2. Rising Awareness Regarding Safety of Donated Blood
      • 5.3.1.3. Increase in Patient Affordability to Pay for NAT Tested Blood
      • 5.3.1.4. Growing Adoption of NAT for Blood Screening
      • 5.3.1.5. Increasing Demand of Donated Blood
      • 5.3.1.6. Rising Prevalence of Infectious Diseases
    • 5.3.2. Restraints
      • 5.3.2.1. Capital Expenditure and Operating Cost of NAT Testing
      • 5.3.2.2. Lack of Mandate for NAT in Developing Countries
      • 5.3.2.3. Digital Immunoassay is New Alternative Technology
    • 5.3.3. Opportunities
      • 5.3.3.1. Pathogen Reduction Technology
      • 5.3.3.2. Microbiology Screening
      • 5.3.3.3. Multiplexing (Single Test for HIV, HBV, & HCV)
    • 5.3.4. Challenges
      • 5.3.4.1. Price Reduction
      • 5.3.4.2. Lack of Trained Manpower
      • 5.3.4.3. Regulatory Challenges

6. Industry Trends

  • 6.1. Supply Chain Analysis
  • 6.2. Pest Analysis
    • 6.2.1. Political Factors
    • 6.2.2. Economic Factors
    • 6.2.3. Social Factors
    • 6.2.4. Technical Factors
  • 6.3. Porter's Five Force Analysis
    • 6.3.1. Threat From New Entrants
    • 6.3.2. Threat From Substitute Technologies
    • 6.3.3. Bargaining Power of Suppliers
    • 6.3.4. Bargaining Power of Buyers
    • 6.3.5. Intensity of Competitive Rivalry

7. Blood Screening Market, By Technology

  • 7.1. Introduction
  • 7.2. Blood Screening Market, By Volume (Number of Tests Conducted)
    • 7.2.1. Transcription-Mediated Amplification
    • 7.2.2. Real-Time Polymerase Chain Reaction (PCR)
  • 7.3. Enzyme-Linked Immunosarbent Assay (ELISA)
    • 7.3.1. Rapid Test (Card Methodology)
    • 7.3.2. 1st Generation ELISA
    • 7.3.3. 2nd Generation ELISA
    • 7.3.4. 3rd Generation ELISA
    • 7.3.5. 4th Generation ELISA
  • 7.5. Next-Generation Sequencing (NGS)
  • 7.6. Western Blot Assay

8. Blood Screening Market, By Products and Services

  • 8.1. Introduction
  • 8.2. Instruments (Hardware)
    • 8.2.1. Rental Purchase
    • 8.2.2. Outright Purchase
  • 8.3. Reagents
    • 8.3.1. ELISA Reagents
      • 8.3.1.1. Immunosorbent
      • 8.3.1.2. Controls
      • 8.3.1.3. Conjugate (Antigen Or Antibody Conjugated Enzyme)
      • 8.3.1.4. Substrate (Substrate of Enzyme)
      • 8.3.1.5. Sample Diluents and Wash Solutions
    • 8.3.2. NAT Reagents
      • 8.3.2.1. Enzymes and Polymerases
      • 8.3.2.2. Standards and Controls
      • 8.3.2.3. Probes & Primers
      • 8.3.2.4. Buffers, Nucleotides, and Solutions
      • 8.3.2.5. Labeling & Detection Reagents
    • 8.3.3. Other Reagents
  • 8.4. Software and Services

9. Blood Screening Market, By End User

  • 9.1. Introduction
  • 9.2. Blood Banks
  • 9.3. Hospitals

10. Blood Screening Market, By Region

  • 10.1. Introduction
    • 10.1.1. North America
    • 10.1.2. U.S.
    • 10.1.3. Canada
  • 10.2. Europe
    • 10.2.1. Germany
    • 10.2.2. France
    • 10.2.3. U.K.
    • 10.2.4. Italy
    • 10.2.5. Spain
    • 10.2.6. Rest of Europe (ROE)
  • 10.3. Asia
    • 10.3.1. Japan
    • 10.3.2. China
    • 10.3.3. India
    • 10.3.4. Rest of Asia (ROA)
  • 10.4. Rest of the World (ROW)

11. Competitive Landscape

  • 11.1. Overview
  • 11.2. Market Share Analysis
    • 11.2.1. Market Share Analysis for NAT
    • 11.2.2. Market Share Analysis for Blood Screening
  • 11.3. Competitive Situations and Trends
    • 11.3.1. New Product Launches
    • 11.3.2. Mergers and Acquisitions
    • 11.3.3. Regulatory Approvals
    • 11.3.4. Partnerships and Agreements

12. Company Profiles

  • 12.1. Introduction
  • 12.2. Grifols
    • 12.2.1. Business Overview
    • 12.2.2. Product Portfolio
    • 12.2.3. Key Strategy
    • 12.2.4. Recent Developments
    • 12.2.5. MNM View
  • 12.3. Roche Diagnostics (A Division of F. Hoffmann-La Roche Ltd)
    • 12.3.1. Business Overview
    • 12.3.2. Product Portfolio
    • 12.3.3. Key Strategy
    • 12.3.4. Recent Developments
    • 12.3.5. MNM View
  • 12.4. Abbott Laboratories
    • 12.4.1. Business Overview
    • 12.4.2. Product Portfolio
    • 12.4.3. Key Strategy
    • 12.4.4. Recent Developments
    • 12.4.5. MNM View
  • 12.5. Biomérieux
    • 12.5.1. Business Overview
    • 12.5.2. Product Portfolio
    • 12.5.3. Key Strategy
    • 12.5.4. Recent Developments
    • 12.5.5. MNM View
  • 12.6. Bio-Rad Laboratories, Inc.
    • 12.6.1. Business Overview
    • 12.6.2. Product Portfolio
    • 12.6.3. Key Strategy
    • 12.6.4. Recent Developments
    • 12.6.5. MNM View
  • 12.7. Siemens Healthcare (Subsidiary of Siemens AG)
    • 12.7.1. Business Overview
    • 12.7.2. Product Portfolio
    • 12.7.3. Key Strategy
    • 12.7.4. Recent Developments
  • 12.8. Ortho-Clinical Diagnostics, Inc.
    • 12.8.1. Business Overview
    • 12.8.2. Product Portfolio
    • 12.8.3. Key Strategy
    • 12.8.4. Recent Developments
  • 12.9. Thermo Fisher Scientific, Inc.
    • 12.9.1. Business Overview
    • 12.9.2. Product Portfolio
    • 12.9.3. Key Strategy
    • 12.9.4. Recent Development
  • 12.1. Beckman Coulter (Subsidiary of Danaher Corporation)
    • 12.10.1. Business Overview
    • 12.10.2. Product Portfolio
    • 12.10.3. Key Strategy
    • 12.10.4. Recent Developments
  • 12.11. Becton, Dickinson and Company
    • 12.11.1. Business Overview
    • 12.11.2. Product Portfolio
    • 12.11.3. Key Strategy
    • 12.11.4. Recent Developments

13. Appendix

List of Tables

  • Table 1: Blood Screening Market Size, By Technology, 2012-2019 ($Million)
  • Table 2: Global Market, By Volume (Number of Tests), 2014
  • Table 3: North America: Blood Screening Market, By Volume (Number of Tests), 2014
  • Table 4: Europe: Market, By Volume (Number of Tests),2014
  • Table 5: Asia: Market, By Volume (Number of Tests), 2014
  • Table 6: Blood Screening NAT Technology Market Size, By Region, 2012-2019 ($Million)
  • Table 7: North America: Blood Screening NAT Technology Market Size, By Country, 2012-2019 ($Million)
  • Table 8: Europe: Blood Screening NAT Technology Market Size, By Country/Region, 2012-2019 ($Million)
  • Table 9: Asia: Blood Screening NAT Technology Market Size, By Country/Region, 2012-2019 ($Million)
  • Table 10: North America: Blood Screening NAT Technology Market Size, By Type, 2012-2019 ($Million)
  • Table 11: Transcription-Mediated Amplification Technology Market Size, By Region, 2012-2019 ($Million)
  • Table 12: North America: Transcription-Mediated Amplification Technology Market Size, By Country, 2012-2019 ($Million)
  • Table 13: Europe: Transcription-Mediated Amplification Technology Market Size, By Country/Region, 2012-2019 ($Million)
  • Table 14: Asia: Transcription-Mediated Amplification Technology Market Size, By Country/Region, 2012-2019 ($Million)
  • Table 15: Real-Time PCR Technology Market Size, By Region, 2012-2019 ($Million)
  • Table 16: North America: Real-Time PCR Technology Market Size, By Country, 2012-2019 ($Million)
  • Table 17: Europe: Real-Time PCR Technology Market Size, By Country/Region, 2012-2019 ($Million)
  • Table 18: Asia Real-Time PCR Technology Market Size, By Country/Region, 2012-2019 ($Million)
  • Table 19: ELISA Market Size, By Region, 2012-2019 ($Million)
  • Table 20: North America: ELISA Market Size, By Country, 2012-2019 ($Million)
  • Table 21: Europe: ELISA Market Size, By Country/Region, 2012-2019 ($Million)
  • Table 22: Asia: ELISA Market Size, By Country/Region, 2012-2019 ($Million)
  • Table 23: ELISA Market Size, By Type, 2012-2019 ($Million)
  • Table 24: Rapid Test (Card Methodology) Market Size, By Region, 2012-2019 ($Million)
  • Table 25: North America: Rapid Test (Card Methodology) Market Size, By Country, 2012-2019 ($Million)
  • Table 26: Europe: Rapid Test (Card Methodology) Market Size, By Country/Region, 2012-2019 ($Million)
  • Table 27: Asia: Rapid Test (Card Methodology) Market Size, By Country/Region, 2012-2019 ($Million)
  • Table 28: 1st Generation ELISA Market Size, By Region, 2012-2019 ($Million)
  • Table 29: North America: 1st Generation ELISA Market Size, By Country, 2012-2019 ($Million)
  • Table 30: Europe: 1st Generation ELISA Market Size, By Country/Region, 2012-2019 ($Million)
  • Table 31: Asia: 1st Generation ELISA Market Size, By Country/Region, 2012-2019 ($Million)
  • Table 32: 2nd Generation ELISA Market Size, By Region, 2012-2019 ($Million)
  • Table 33: North America: 2nd Generation ELISA Market Size, By Region, 2012-2019 ($Million)
  • Table 34: Europe: 2nd Generation ELISA Market Size, By Country/Region, 2012-2019 ($Million)
  • Table 35: Asia: 2nd Generation ELISA Market Size, By Country/Region, 2012-2019 ($Million)
  • Table 36: 3rd Generation ELISA Market Size, By Region, 2012-2019 ($Million)
  • Table 37: North America: 3rd Generation ELISA Market Size, By Country, 2012-2019 ($Million)
  • Table 38: Europe: 3rd Generation ELISA Market Size, By Country/Region, 2012-2019 ($Million)
  • Table 39: Asia: 3rd Generation ELISA Market Size, By Country/Region, 2012-2019 ($Million)
  • Table 40: 4th Generation ELISA Market Size, By Region, 2012-2019 ($Million)
  • Table 41: North America: 4th Generation ELISA Market Size, By Country, 2012-2019 ($Million)
  • Table 42: Europe: 4th Generation ELISA Market Size, By Country/Region, 2012-2019 ($Million)
  • Table 43: Asia: 4th Generation ELISA Market Size, By Country/Region, 2012-2019 ($Million)
  • Table 44: EIAS and CLIAS Market Size, By Region, 2012-2019 ($Million)
  • Table 45: North America: EIAS and CLIAS Market Size, By Region, 2012-2019 ($Million)
  • Table 46: Europe: EIAS and CLIAS Market Size, By Country/Region, 2012-2019 ($Million)
  • Table 47: Asia: EIAS and CLIAS Market Size, By Country/Region, 2012-2019 ($Million)
  • Table 48: NGS Market Size, By Region, 2012-2019 ($Million)
  • Table 49: North America: NGS Market Size, By Region, 2012-2019 ($Million)
  • Table 50: Europe: NGS Market Size, By Country/Region, 2012-2019 ($Million)
  • Table 51: Asia: NGS Market Size, By Country/Region, 2012-2019 ($Million)
  • Table 52: Western Blot Assay Market Size, By Region, 2012-2019 ($Million)
  • Table 53: North America: Western Blot Assay Market Size, By Country, 2012-2019 ($Million)
  • Table 54: Europe: Western Blot Assay Market Size, By Country/Region, 2012-2019 ($Million)
  • Table 55: Asia: Western Blot Assay Market Size, By Country/Region, 2012-2019 ($Million)
  • Table 56: Blood Screening Market Size, By Products and Services, 2012-2019 ($Million)
  • Table 57: Blood Screening Instruments Market Size, By Region, 2012-2019 ($Million)
  • Table 58: North America: Blood Screening Instruments Market Size, By Country, 2012-2019 ($Million)
  • Table 59: Europe: Instruments Market Size, By Country, 2012-2019 ($Million)
  • Table 60: Asia: Instruments Market Size, By Country, 2012-2019 ($Million)
  • Table 61: Instruments Market Size, By Mode of Purchase, 2012-2019 ($Million)
  • Table 62: Reagents Market Size, By Region, 2012-2019 ($Million)
  • Table 63: North America: Blood Screening Reagents Market Size, By Country, 2012-2019 ($Million)
  • Table 64: Europe: Blood Screening Reagents Market Size, By Country, 2012-2019 ($Million)
  • Table 65: Asia: Reagents Market Size, By Country, 2012-2019 ($Million)
  • Table 66: Reagents Market Size, By Type, 2012-2019 ($Million)
  • Table 67: Blood Screening ELISA Reagents Market Size, By Region, 2012-2019 ($Million)
  • Table 68: North America: ELISA Reagents Market Size, By Country, 2012-2019 ($Million)
  • Table 69: Europe: ELISA Reagents Market Size, By Country, 2012-2019 ($Million)
  • Table 70: Asia: ELISA Reagents Market Size, By Country, 2012-2019 ($Million)
  • Table 71: ELISA Reagents Market Size, By Type, 2012-2019 ($Million)
  • Table 72: Blood Screening NAT Reagents Market Size, By Region, 2012-2019 ($Million)
  • Table 73: North America: NAT Reagents Market Size, By Country, 2012-2019 ($Million)
  • Table 74: Europe: NAT Reagents Market Size, By Country, 2012-2019 ($Million)
  • Table 75: Asia: NAT Reagents Market Size, By Country, 2012-2019 ($Million)
  • Table 76: NAT Reagents Market Size, By Type, 2012-2019 ($Million)
  • Table 77: Blood Screening Other Reagents Market Size, By Region, 2012-2019 ($Million)
  • Table 78: North America: Other Reagents Market Size, By Country, 2012-2019 ($Million)
  • Table 79: Europe: Other Reagents Market Size, By Country, 2012-2019 ($Million)
  • Table 80: Asia: Other Reagents Market Size, By Country, 2012-2019 ($Million)
  • Table 81: Software and Services Market Size, By Region, 2012-2019 ($Million)
  • Table 82: North America: Blood Screening Software and Services Market Size, By Country, 2012-2019 ($Million)
  • Table 83: Europe: Software and Services Market Size, By Region, 2012-2019 ($Million)
  • Table 84: Asia: Software and Services Market Size, By Country, 2012-2019 ($Million)
  • Table 85: Blood Screening Market Size, By End User, 2012-2019 ($Million)
  • Table 86: Market Size for Blood Banks, By Region, 2012-2019 ($Million)
  • Table 87: North America: Market Size for Blood Banks, By Country, 2012-2019 ($Million)
  • Table 88: Europe: Market Size for Blood Banks, By Country, 2012-2019 ($Million)
  • Table 89: Asia: Market Size for Blood Banks, By Country, 2012-2019 ($Million)
  • Table 90: Blood Screening Market Size for Hospitals, By Region, 2012-2019 ($Million)
  • Table 91: North America: Blood Screening Market Size for Hospitals, By Country, 2012-2019 ($Million)
  • Table 92: Europe: Market Size for Hospitals, By Country, 2012-2019 ($Million)
  • Table 93: Asia: Market Size for Hospitals, By Country, 2012-2019 ($Million)
  • Table 94: Global Blood Screening Market Size, By Region, 2012-2019 ($Million)
  • Table 95: North America: Blood Screening Market Size, By Country, 2012-2019 ($Million)
  • Table 96: Europe: Market Size, By Country, 2012-2019 ($Million)
  • Table 97: Asia: Market Size, By Country, 2012-2019 ($Million)
  • Table 98: North America: Market Size, By Technology, 2012-2019 ($Million)
  • Table 99: North America: Market Size for NAT, By Type, 2012-2019 ($Million)
  • Table 100: North America: Market Size for ELISA, By Type, 2012-2019 ($Million)
  • Table 101: North America: Market Size, By Products and Services, 2012-2019 ($Million)
  • Table 102: North America: Market Size for Reagents, By Type, 2012-2019 ($Million)
  • Table 103: North America: Market Size, By End User, 2012-2019 ($Million)
  • Table 104: U.S.: Blood Screening Market Size, By Technology, 2012-2019 ($Million)
  • Table 105: U.S.: Market Size for NAT, By Type, 2012-2019 ($Million)
  • Table 106: U.S.: Market Size for ELISA, By Type, 2012-2019 ($Million)
  • Table 107: U.S.: Market Size, By Products & Services, 2012-2019 ($Million)
  • Table 108: U.S.: Market Size for Reagents, By Type, 2012-2019 ($Million)
  • Table 109: U.S.: Market Size, By End User, 2012-2019 ($Million)
  • Table 110: Canada: Blood Screening Market Size, By Technology, 2012-2019 ($Million)
  • Table 111: Canada: Market Size for NAT, By Type, 2012-2019 ($Million)
  • Table 112: Canada: Market Size for ELISA, By Type, 2012-2019 ($Million)
  • Table 113: Canada: Market Size, By Products & Services, 2012-2019 ($Million)
  • Table 114: Canada: Market Size for Reagents, By Type, 2012-2019 ($Million)
  • Table 115: Canada: Market Size, By End User, 2012-2019 ($Million)
  • Table 116: Europe: Market Size, By Technology, 2012-2019 ($Million)
  • Table 117: Europe: Market Size for NAT, By Type, 2012-2019 ($Million)
  • Table 118: Europe: Market Size for ELISA, By Type, 2012-2019 ($Million)
  • Table 119: Europe: Market Size, By Products and Services, 2012-2019 ($Million)
  • Table 120: Europe: Market Size for Reagents, By Type, 2012-2019 ($Million)
  • Table 121: Europe: Market Size, By End User, 2012-2019 ($Million)
  • Table 122: Germany: Blood Screening Market Size, By Technology, 2012-2019 ($Million)
  • Table 123: Germany: Market Size for NAT, By Type, 2012-2019 ($Million)
  • Table 124: Germany: Market Size for ELISA, By Type, 2012-2019 ($Million)
  • Table 125: Germany: Market Size, By Products & Services, 2012-2019 ($Million)
  • Table 126: Germany: Market Size for Reagents, By Type, 2012-2019 ($Million)
  • Table 127: Germany: Market Size, By End User, 2012-2019 ($Million)
  • Table 128: France: Blood Screening Market Size, By Technology, 2012-2019 ($Million)
  • Table 129: France: Market Size for NAT, By Type, 2012-2019 ($Million)
  • Table 130: France: Market Size for ELISA, By Type, 2012-2019 ($Million)
  • Table 131: France: Market Size, By Products & Services, 2012-2019 ($Million)
  • Table 132: France: Market Size for Reagents, By Type, 2012-2019 ($Million)
  • Table 133: France: Market Size, By End User, 2012-2019 ($Million)
  • Table 134: U.K.: Blood Screening Market Size, By Technology, 2012-2019 ($Million)
  • Table 135: U.K.: Market Size for NAT, By Type, 2012-2019 ($Million)
  • Table 136: U.K.: Market Size for ELISA, By Type, 2012-2019 ($Million)
  • Table 137: U.K.: Market Size, By Products & Services, 2012-2019 ($Million)
  • Table 138: U.K.: Market Size for Reagents, By Type, 2012-2019 ($Million)
  • Table 139: U.K.: Market Size, By End User, 2012-2019 ($Million)
  • Table 140: Italy: Blood Screening Market Size, By Technology, 2012-2019 ($Million)
  • Table 141: Italy: Market Size for NAT, By Type, 2012-2019 ($Million)
  • Table 142: Italy: Market Size for ELISA, By Type, 2012-2019 ($Million)
  • Table 143: Italy: Market Size, By Products & Services, 2012-2019 ($Million)
  • Table 144: Italy: Market Size for Reagents, By Type, 2012-2019 ($Million)
  • Table 145: Italy: Market Size, By End User, 2012-2019 ($Million)
  • Table 146: Spain: Blood Screening Market Size, By Technology, 2012-2019 ($Million)
  • Table 147: Spain: Market Size for NAT, By Type, 2012-2019 ($Million)
  • Table 148: Spain: Market Size for ELISA, By Type, 2012-2019 ($Million)
  • Table 149: Spain: Market Size, By Products & Services, 2012-2019 ($Million)
  • Table 150: Spain: Blood Screening Market Size for Reagents, By Type, 2012-2019 ($Million)
  • Table 151: Spain: Blood Screening Market Size, By End User, 2012-2019 ($Million)
  • Table 152: ROE: Blood Screening Market Size, By Technology, 2012-2019 ($Million)
  • Table 153: ROE: Market Size for NAT, By Type, 2012-2019 ($Million)
  • Table 154: ROE: Market Size for ELISA, By Type, 2012-2019 ($Million)
  • Table 155: ROE: Market Size, By Products & Services, 2012-2019 ($Million)
  • Table 156: ROE: Blood Screening Market Size for Reagents, By Type, 2012-2019 ($Million)
  • Table 157: ROE: Blood Screening Market Size, By End User, 2012-2019 ($Million)
  • Table 158: Asia: Blood Screening Market Size, By Technology, 2012-2019 ($Million)
  • Table 159: Asia: Market Size for NAT, By Type, 2012-2019 ($Million)
  • Table 160: Asia: Blood Screening Market Size for ELISA, By Type, 2012-2019 ($Million)
  • Table 161: Asia: Market Size, By Products & Services, 2012-2019 ($Million)
  • Table 162: Asia: Blood Screening Market Size for Reagents, By Type, 2012-2019 ($Million)
  • Table 163: Asia: Market Size, By End User, 2012-2019 ($Million)
  • Table 164: Japan: Blood Screening Market Size, By Technology, 2012-2019 ($Million)
  • Table 165: Japan: Market Size for NAT, By Type, 2012-2019 ($Million)
  • Table 166: Japan: Blood Screening Market Size for ELISA, By Type, 2012-2019 ($Million)
  • Table 167: Japan: Market Size, By Products & Services, 2012-2019 ($Million)
  • Table 168: Japan: Blood Screening Market Size for Reagents, By Type, 2012-2019 ($Million)
  • Table 169: Japan: Market Size, By End User, 2012-2019 ($Million)
  • Table 170: China: Blood Screening Market Size, By Technology, 2012-2019 ($Million)
  • Table 171: China: Market Size for NAT, By Type, 2012-2019 ($Million)
  • Table 172: China: Blood Screening Market Size for ELISA, By Type, 2012-2019 ($Million)
  • Table 173: China: Market Size, By Products & Services, 2012-2019 ($Million)
  • Table 174: China: Blood Screening Market Size for Reagents, By Type, 2012-2019 ($Million)
  • Table 175: China: Market Size, By End User, 2012-2019 ($Million)
  • Table 176: India: Blood Screening Market Size, By Technology, 2012-2019 ($Million)
  • Table 177: India: Market Size for NAT, By Type, 2012-2019 ($Million)
  • Table 178: India: Blood Screening Market Size for ELISA, By Type, 2012-2019 ($Million)
  • Table 179: India: Market Size, By Products & Services, 2012-2019 ($Million)
  • Table 180: India: Blood Screening Market Size for Reagents, By Type, 2012-2019 ($Million)
  • Table 181: India: Market Size, By End User, 2012-2019 ($Million)
  • Table 182: ROA: Blood Screening Market Size, By Technology, 2012-2019 ($Million)
  • Table 183: ROA: Market Size for NAT, By Type, 2012-2019 ($Million)
  • Table 184: ROA: Market Size for ELISA, By Type, 2012-2019 ($Million)
  • Table 185: ROA: Market Size, By Products & Services, 2012-2019 ($Million)
  • Table 186: ROA: Market Size for Reagents, By Type, 2012-2019 ($Million)
  • Table 187: ROA: Market Size, By End User, 2012-2019 ($Million)
  • Table 188: ROW: Blood Screening Market Size, By Technology, 2012-2019 ($Million)
  • Table 189: ROW: Market Size for NAT, By Type, 2012-2019 ($Million)
  • Table 190: ROW: Blood Screening Market Size for ELISA, By Type, 2012-2019 ($Million)
  • Table 191: ROW: Market Size, By Products & Services, 2012-2019 ($Million)
  • Table 192: ROW: Market Size for Reagents, By Type, 2012-2019 ($Million)
  • Table 193: ROW: Market Size, By End User, 2012-2019 ($Million)
  • Table 194: New Product Launches
  • Table 195: Mergers and Acquisitions
  • Table 196: Regulatory Approvals
  • Table 197: Partnerships and Agreements

List of Figures

  • Figure 1: Research Methodology
  • Figure 2: Top-Down Approach
  • Figure 3: Bottom-Up Approach
  • Figure 4: Breakdown of Primary Interviews: By Company Type, Designation, and Region
  • Figure 1: Blood Screening Market Snapshot, By Technology (2014 vs. 2019)
  • Figure 2: Reagents Segment Dominates Blood Screening Market With the CAGR of 10.9% During Forecasted Period
  • Figure 3: 4th Generation ELISA is Largest Segment in 2014 Blood Screening ELISA Market and Would Continue Its Growth Story Till 2019
  • Figure 4: Blood Banks Segment is Largest Contributor and Fastest Growing Segment in Blood Screening Market During Forecasted Period
  • Figure 5: Global Blood Screening Market, By Region: North America Holds Largest Share and Asia is Fastest Growing Region in 2014
  • Figure 6: NAT Segment to Offer Attractive Growth Opportunities
  • Figure 7: Blood Screening Reagents Segment to Grow at Highest Rate
  • Figure 8: NAT Reagents Contributes Highest Share in Blood Screening Reagents Market
  • Figure 9: 4th Generation ELISA Segment Expected to Grow at Highest CAGR in Asia During Forecasted Period
  • Figure 10: Blood Banks Dominates in Blood Screening Market and Witness Highest CAGR During Forecasted Period
  • Figure 11: China to Witness Highest Growth in Forecast Period
  • Figure 12: Technological Innovation and Differentiated Products Are Increasing Competition Among Market Players
  • Figure 13: NAT Testing Will Continue to Dominate the Market During the Forecast Period
  • Figure 14: Real-Time PCR Expected to Grow at A Double-Digit CAGR From 2014 to 2019
  • Figure 15: Asian 4th Generation ELISA Market Expected to Double By 2019
  • Figure 16: Reagents Segment Will Continue to Dominate the Blood Screening Market During Forecast Period
  • Figure 17: Asia is the Fastest-Growing Region in the Blood Screening Reagent Market
  • Figure 18: China to Witness the Highest Growth in the Blood Screening NAT Reagents Market in Asia
  • Figure 19: Blood Screening Market Segmentation, By End User
  • Figure 20: Blood Banks Segment Will Continue to Dominate the Blood Screening Market During the Forecast Period
  • Figure 21: Geographic Snapshot (2014): Emerging Markets Offer Significant Growth Opportunities in the Blood Screening Market
  • Figure 22: North America: Market Growth Will Be Driven By Innovative Blood Screening Instruments and Reagents
  • Figure 23: China Offers Immense Growth Opportunities for the Blood Screening Market
  • Figure 24: Battle for Market Share: New Product Launches Was the Key Strategy
  • Figure 25: Product Benchmarking for Top 5 Players
  • Figure 26: Grifols: Company Snapshot
  • Figure 27: Roche Diagnostics: Company Snapshot
  • Figure 28: Abbott Laboratories: Company Snapshot
  • Figure 29: Biomérieux: Company Snapshot
  • Figure 30: Bio-Rad Laboratories, Inc.: Company Snapshot
  • Figure 31: Siemens AG : Company Snapshot
  • Figure 32: Thermo Fisher Scientific, Inc.: Company Snapshot
  • Figure 33: Danaher Corporation: Company Snapshot
  • Figure 34: Becton, Dickinson and Company: Company Snapshot
Back to Top